Aurobindo Pharma

Which are the latest news on Aurobindo Pharma?

Why is Aurobindo Pharma Ltd. falling/rising?

As of 23-Jun, Aurobindo Pharma Ltd. is seeing a stock price increase to 1,535.50, up 2.89%. This rise is driven by strong performance against the Sensex, positive technical indicators, and solid financial health, including being net-debt free and high institutional holdings.

As of 23-Jun, Aurobindo Pharma Ltd. is experiencing a rise in its stock price, currently at 1,535.50, reflecting an increase of 43.2 points or 2.89%. This upward movement can be attributed to several factors highlighted in the data. <BR><BR>Firstly, the stock has shown strong performance relative to the benchmark Sensex, with a 10.06% increase over the past week, while the Sensex has declined by 0.79%. Additionally, Aurobindo Pharma has outperformed the sector by 1.78% today, indicating robust market interest. The stock also reached an intraday high of Rs 1542.6, marking a rise of 3.37% during the trading day.<BR><BR>Moreover, Aurobindo Pharma is trading above all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), which is a positive technical indicator suggesting strong momentum. The rising investor participation is also notable, with a delivery volume of 8.94 lacs on June 22, which has increased by 1.29% compared to the 5-day average, indicating growing confidence among investors.<BR><BR>The company’s financial health further supports its rising stock price, as it is net-debt free and has a return on equity (ROE) of 9.4, suggesting a fair valuation. High institutional holdings at 41.11% reflect confidence from more sophisticated investors who have the resources to analyze the company's fundamentals effectively.<BR><BR>Overall, Aurobindo Pharma Ltd.'s strong recent performance, positive market sentiment, and solid financial standing contribute to the rise in its stock price.

How big is Aurobindo Pharma?

As of 10th June, Aurobindo Pharma Ltd. has a market capitalization of 83,955.00 Cr, with net sales of 33,653.08 Cr and a net profit of 3,504.75 Cr reported in the latest four quarters.

As of 10th June, Aurobindo Pharma Ltd. has a market capitalization of 83,955.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Aurobindo Pharma reported net sales of 33,653.08 Cr and a net profit of 3,504.75 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 32,653.32 Cr and total assets of 48,492.01 Cr.

Who are in the management team of Aurobindo Pharma?

The management team of Aurobindo Pharma includes Chairman K Ragunathan, Executive Directors Kambam Nityananda Reddy, M Sivakumaran, and M Madan Mohan Reddy, along with several independent and non-executive directors, bringing diverse expertise to the company.

The management team of Aurobindo Pharma includes the following individuals:<BR><BR>1. **K Ragunathan** - Chairman & Independent Director<BR>2. **Kambam Nityananda Reddy** - Executive Director<BR>3. **M Sivakumaran** - Executive Director<BR>4. **M Madan Mohan Reddy** - Executive Director<BR>5. **P V Ramprasad Reddy** - Non-Executive Director<BR>6. **Avnit Bimal Singh** - Independent Non-Executive Director<BR>7. **Savita Mahajan** - Independent Non-Executive Director<BR>8. **Girish Paman Vanvari** - Independent Non-Executive Director<BR>9. **P Sarath Chandra Reddy** - Independent Non-Executive Director<BR>10. **Santanu Mukherjee** - Independent Director<BR><BR>This diverse team brings a range of expertise and leadership to the company.

Who are the peers of the Aurobindo Pharma?

Aurobindo Pharma's peers include Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Laurus Labs, Biocon, Alkem Lab, and Glenmark Pharma. Aurobindo Pharma has average management risk and below average growth, with a 1-year return of 26.42%, while Laurus Labs leads with a 1-year return of 106.82%.

Peers: Aurobindo Pharma's peers include Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Laurus Labs, Biocon, Alkem Lab, and Glenmark Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, and Glenmark Pharma, while Average management risk is found at Aurobindo Pharma and Biocon. Good growth is seen at Zydus Lifesci., Lupin, and Mankind Pharma, while Aurobindo Pharma, Laurus Labs, and Biocon exhibit below average growth. Excellent capital structure is noted for Cipla, Zydus Lifesci., Dr Reddy's Labs, Aurobindo Pharma, Alkem Lab, and Glenmark Pharma, while Laurus Labs and Biocon have average and below average capital structures, respectively.<BR><BR>Return Snapshot: Laurus Labs has the highest 1-year return at 106.82%, while Abbott India has the lowest at -16.53%. Aurobindo Pharma's 1-year return of 26.42% is significantly higher than Abbott India's. Additionally, Alkem Lab and Abbott India have negative six-month returns.

What does Aurobindo Pharma do?

Aurobindo Pharma Ltd. is a prominent pharmaceutical and biotechnology company that develops, manufactures, and markets active pharmaceutical ingredients (APIs), intermediates, and generic formulations. As of March 2026, it reported net sales of 8,853 Cr and a net profit of 921 Cr, with a market capitalization of INR 83,955 Cr.

Overview: <BR>Aurobindo Pharma Ltd. is a leading manufacturer in the pharmaceuticals and biotechnology industry, specializing in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), intermediates, and generic formulations.<BR><BR>History: <BR>Aurobindo Pharma Ltd. was incorporated on December 26, 1986, as a private limited company. It has maintained its status as a private entity since its inception. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8,853 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 921 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 83,955 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.28% <BR>Debt-Equity: -0.07 <BR>Return on Equity: 9.37% <BR>Price to Book: 2.22<BR><BR>Contact Details: <BR>Address: Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet Hyderabad Telangana : 500038 <BR>Tel: 91-40-23736370 <BR>Email: info@aurobindo.com/investorgrievanc <BR>Website: http://www.aurobindo.com

Should I buy, sell or hold Aurobindo Pharma Ltd.?

Are Aurobindo Pharma Ltd. latest results good or bad?

Aurobindo Pharma's latest results show strong revenue growth with record quarterly net sales of ₹8,853 crore, but profitability declined slightly with a net profit of ₹921 crore and reduced operating margins, indicating operational challenges. Investors may see solid sales performance but should be cautious about profitability issues.

Aurobindo Pharma's latest results present a mixed picture. On one hand, the company achieved its highest-ever quarterly net sales of ₹8,853 crore for Q4 FY26, reflecting a strong year-on-year growth of 5.62% and a quarter-on-quarter increase of 2.40%. This consistent revenue growth indicates the company's ability to capture market share, particularly in key markets like the United States and Europe.<BR><BR>However, the profitability metrics raise concerns. The consolidated net profit for the quarter was ₹921 crore, which represents a decline of 1.97% year-on-year, although it did show a slight improvement of 1.21% compared to the previous quarter. Additionally, the operating margin decreased to 20.03%, down from 21.38% a year ago, indicating ongoing margin pressures due to rising operational costs, particularly employee expenses.<BR><BR>Overall, while the revenue growth is commendable, the decline in profitability and margins suggests that Aurobindo Pharma is facing significant operational challenges. Investors might view the results as a sign of robust sales performance but remain cautious due to the underlying profitability concerns.

When is the next results date for Aurobindo Pharma Ltd.?

Aurobindo Pharma Ltd. will announce its results on 21 May 2026.

Aurobindo Pharma Ltd. will declare its results on 21 May 2026.

Is Aurobindo Pharma technically bullish or bearish?

As of December 1, 2025, Aurobindo Pharma's technical trend is mildly bullish, supported by daily moving averages and a bullish weekly MACD, but tempered by mixed signals from other indicators like the monthly MACD and Bollinger Bands.

As of 1 December 2025, the technical trend for Aurobindo Pharma has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The daily moving averages are bullish, supporting the mildly bullish stance. However, the Bollinger Bands show a bearish signal on the monthly chart, which adds caution. The KST is bullish on the weekly but mildly bearish on the monthly, and both the Dow Theory and OBV indicate no clear trend. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and weekly MACD, but tempered by mixed signals from other indicators.

How has been the historical performance of Aurobindo Pharma?

Aurobindo Pharma has shown consistent growth in net sales and profits, with net sales increasing from ₹19,563.55 Cr in March 2019 to ₹31,723.73 Cr in March 2025, and profit after tax rising from ₹1,939.32 Cr to ₹3,515.26 Cr during the same period, indicating strong financial health and enhanced shareholder value.

Answer:<BR>The historical performance of Aurobindo Pharma shows a consistent growth trajectory in net sales and profits over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Aurobindo Pharma's net sales have increased from 19,563.55 Cr in March 2019 to 31,723.73 Cr in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from 24,855.38 Cr in March 2023 to 31,723.73 Cr in March 2025. The company's operating profit (PBDIT) also improved significantly, reaching 7,204.64 Cr in March 2025, compared to 4,009.23 Cr in March 2023. Profit before tax increased from 2,624.17 Cr in March 2023 to 5,097.98 Cr in March 2025, while profit after tax rose from 1,939.32 Cr to 3,515.26 Cr in the same period. The earnings per share (EPS) grew from 32.9 in March 2023 to 60.02 in March 2025, indicating enhanced shareholder value. On the balance sheet, total assets increased from 39,212.50 Cr in March 2023 to 48,492.01 Cr in March 2025, alongside total liabilities rising from 39,212.50 Cr to 48,492.01 Cr. Cash flow from operating activities improved from 2,386.00 Cr in March 2023 to 3,924.00 Cr in March 2025, contributing to a net cash inflow of 2,178.00 Cr in March 2025, compared to an outflow of 1,006.00 Cr in March 2024. Overall, Aurobindo Pharma has demonstrated robust growth in revenue and profitability, alongside strengthening financial health over the years.

Is Aurobindo Pharma overvalued or undervalued?

As of November 13, 2025, Aurobindo Pharma is fairly valued with a PE ratio of 20.65 and competitive metrics compared to peers, despite a recent downgrade from attractive, showing a 5.73% return over the past week but a year-to-date decline of -9.68%.

As of 13 November 2025, Aurobindo Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 20.65, an EV to EBITDA of 10.46, and a ROCE of 14.59%. In comparison to its peers, Aurobindo Pharma's valuation metrics are more favorable than those of Sun Pharma, which has a PE ratio of 36.15, and Divi's Lab, which stands at a staggering PE of 70.4.<BR><BR>Despite the recent grade change, Aurobindo Pharma's valuation remains competitive within the pharmaceutical sector, especially when compared to peers like Cipla, which is considered attractive with a PE of 22.65, and Dr. Reddy's Labs at 17.86. The company's stock has shown resilience with a 5.73% return over the past week, outperforming the Sensex's 1.40% return, although its year-to-date performance remains negative at -9.68% compared to the Sensex's 8.11%. Overall, Aurobindo Pharma's current valuation suggests it is fairly positioned in the market.

Has Aurobindo Pharma declared dividend?

Aurobindo Pharma has declared a 400% dividend, amounting to ₹1.5 per share, with an ex-date of August 8, 2025. While recent total returns have been negative, longer-term performance shows positive growth.

Aurobindo Pharma Ltd. has declared a 400% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 400%<BR>- Amount per share: 1.5<BR>- Ex-date: 08 Aug 25<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -11.42%, the dividend return was 0.35%, resulting in a total return of -11.07%.<BR><BR>Over the last 6 months, the price return was -9.43%, the dividend return was 0.34%, leading to a total return of -9.09%.<BR><BR>For the 1-year period, the price return was -23.64%, the dividend return was 0.27%, culminating in a total return of -23.37%.<BR><BR>In the 2-year span, the price return was 27.44%, the dividend return was 0.98%, resulting in a total return of 28.42%.<BR><BR>During the last 3 years, the price return was 88.69%, the dividend return was 2.08%, leading to a total return of 90.77%.<BR><BR>Over the past 4 years, the price return was 19.06%, the dividend return was 2.68%, resulting in a total return of 21.74%.<BR><BR>In the 5-year period, the price return was 17.94%, the dividend return was 2.84%, culminating in a total return of 20.78%.<BR><BR>Overall, Aurobindo Pharma has declared a significant dividend, but the recent total returns indicate a mixed performance, particularly in the short term, with negative returns over the last year. However, the longer-term returns show positive growth, suggesting potential recovery and value for investors.

Who are the top shareholders of the Aurobindo Pharma?

The top shareholders of Aurobindo Pharma include promoters holding 33.5%, mutual funds with 18.21%, and foreign institutional investors at 15.33%. HDFC Mutual Fund is the largest public shareholder, owning 4.33%.

The top shareholders of Aurobindo Pharma include a mix of promoters, mutual funds, and foreign institutional investors. The majority shareholders are the promoters, with Rpr Sons Advisors Private Limited and Mrs. P. Suneela Rani holding the largest stake at 33.5%. <BR><BR>In terms of institutional holdings, mutual funds hold 18.21% of the shares through 35 different schemes, while foreign institutional investors (FIIs) account for 15.33% of the holdings. The highest public shareholder is HDFC Mutual Fund, specifically through the HDFC S&P BSE 500 ETF, which holds 4.33%. Additionally, individual investors collectively own 5.47% of the company. <BR><BR>Overall, the ownership structure reflects a strong presence of both promoter and institutional investors.

What is the bonus history of the Aurobindo Pharma?

Aurobindo Pharma's latest bonus issue was a 1:1 bonus announced on July 20, 2015, with a record date of July 21, 2015, allowing shareholders to receive one additional share for each share held.

Aurobindo Pharma has a notable bonus history, with its latest bonus issue being a 1:1 bonus announced on July 20, 2015. The record date for this bonus was July 21, 2015. This means that shareholders received one additional share for every share they held as of the record date.